Why did Clorox (CLX) stock move recently?

On 8/4/2026, Clorox moved +6.5% — Clorox rose sharply after its Aug 3 earnings release beat Q4 sales estimates and provided an upbeat FY2027 outlook with 13-14% sales growth (above the 12.8% consensus) and commentary on improving demand in health/wellness and international segments, plus a sales boost from the Purell/GOJO acquisition. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Clorox (CLX) overvalued or fairly valued?

MarketChacha shows Clorox's valuation in context — a trailing P/E of about 21.7, a forward P/E of about 16.6, a price-to-book of about 141.9 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Clorox's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (2.29×) from reported figures — education, not a rating.

What is Clorox's revenue?

Clorox reported revenue of $7.1B for FY2025, with net profit of $810.0M, per official filings.

What is the share price of Clorox (CLX)?

Clorox last traded at $107.88 (+2.2% on the day), as of 8/19/2026 — a delayed quote shown for education, not investment advice.

Clorox

CLX · NYSE · Consumer Staples · United States

Snapshot

TickerCLX

ExchangeNYSE

SectorConsumer Staples

IndustryHousehold & Personal Products

CountryUnited States

Employees9,200

HeadquartersOakland, United States

Websitewww.thecloroxcompany.com

Filings tracked18

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. The company operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers home care cleaning and disinfecting products, bleach, clog removers, and laundry additives under the Clorox, Clorox2, Pine-Sol, Scentiva, Tilex, Liquid-Plumr, Poett, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand in the United States. The Household segment provides cat litter products under the Fresh Step and Scoop Away brands; bags and wraps under the Glad brand; and grilling products under the Kingsford brand in the United States. The Lifestyle segment offers dressings, dips, seasonings, and sauces primarily under the Hidden Valley brand; water-filtration products under the Brita brand; and natural personal care products under the Burt's Bees brand in the United States. The International segment provides laundry additives, home care products, bags and wraps, cat litter products, water-filtration systems, professional cleaning and disinfecting products, natural personal care products, food, grilling products, and digestive health products internationally primarily under the Clorox, Glad, Poett, Brita, Burt's Bees, Pine-Sol, Ever Clean, Clorinda, Chux and Fresh Step Brands. It also offers vitamins, minerals, and supplement products under the Natural Vitality, RenewLife, NeoCell, and Rainbow Light brands. The company sells its products through mass retailers; grocery outlets; warehouse clubs; dollar stores; home hardware centers; drug, pet, and military stores; third-party and owned e-commerce channels; and distributors, as well as a direct sales force. The company was founded in 1913 and is headquartered in Oakland, California.

Who owns it

Insiders0.7%
Institutions88.5%
Public & other10.8%

1,411 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.8.31%
State Street Corporation6.97%
Vanguard Capital Management LLC6.53%
Invesco Ltd.4.97%
Vanguard Portfolio Management LLC4.80%
Geode Capital Management, LLC2.70%
Van Eck Associates Corporation2.46%
Morgan Stanley1.86%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion2.29×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend2.0% → 11.4%

Margin has expanded by about 9.4 points — the business is getting more profitable.

Return on equity252.3%

Latest ROE of 252.3% — capital is generating a healthy return.

Growth qualityrev -2% · PAT 133%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $1.9B · EPS 1.37

Est. earnings growth -1.5%

Next fiscal year

Rev $7.8B · EPS 6.36

Est. earnings growth +9.5%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$7.1B

Net margin

11.4%

ROE

252.3%

Revenue CAGR (2y)

-1.9%

Profit CAGR (2y)

+133.2%

EPS (FY2025)

6.52

Net profit (FY2025)

$810.0M

Ask MarketChacha about CLX

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Aug 4, 2026
Clorox rose sharply after its Aug 3 earnings release beat Q4 sales estimates and provided an upbeat FY2027 outlook with 13-14% sales growth (above the 12.8% consensus) and commentary on improving demand in health/wellness and international segments, plus a sales boost from the Purell/GOJO acquisition.
source 1 ↗source 2 ↗source 3 ↗· confidence: high
Jul 27, 2026
No specific company catalyst identified for the move; Clorox is expected to report earnings soon and options activity signaled potential volatility ahead of results, but the stock moved with broader market or sector flows.
source 1 ↗source 2 ↗· confidence: low

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$7.1B	$810.0M	6.52	11.4%	252.3%
FY2024	$7.1B	$280.0M	2.25	3.9%	85.4%
FY2023	$7.4B	$149.0M	1.20	2.0%	67.7%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$1.7B	$187.0M	1.54	11.2%
2025Q4	$1.7B	$157.0M	1.29	9.4%
2025Q3	$1.4B	$80.0M	0.65	5.6%
2025Q1	$1.7B	$186.0M	1.50	11.2%
2024Q4	$1.7B	$193.0M	1.54	11.4%
2024Q3	$1.8B	$99.0M	0.80	5.6%
2024Q1	$1.8B	$-51.0M	-0.41	-2.8%
2023Q4	$2.0B	$93.0M	0.75	4.7%
2023Q3	$1.4B	$22.0M	0.17	1.6%
2023Q1	$1.9B	$-211.0M	-1.71	-11.0%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-K filing
SEC8/7/2026
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC8/3/2026material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC6/17/2026material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC5/28/2026material
8-K — Other events, Exhibits
SEC5/11/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC4/30/2026material
10-Q filing
SEC4/30/2026
8-K — Reg FD disclosure, Other events, Exhibits
SEC4/1/2026material
8-K — Material agreement, Material financial obligation, Exhibits
SEC3/10/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC2/3/2026material
10-Q filing
SEC2/3/2026
8-K — Reg FD disclosure, Other events, Exhibits
SEC1/22/2026material

2025

8-K — Shareholder vote results, Exhibits
SEC11/20/2025material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC11/3/2025material
10-Q filing
SEC11/3/2025
8-K — Executive/director change
SEC10/30/2025material
10-K filing
SEC8/8/2025
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC7/31/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.